Mouthwash With Chlorhexidine 0.12%/Ethyl Alcohol 7% Compared to Ethyl Alcohol 7%
NCT ID: NCT02414581
Last Updated: 2018-05-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
60 participants
INTERVENTIONAL
2015-04-30
2016-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Green Tea Mouthwash on the Oral Health Status in Oral Cancer Patients
NCT04615780
Using a Steroid Mouthwash to Prevent Mouth Sores During Chemotherapy
NCT07287826
Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis
NCT02606994
Ectoin® Mouth Wash for the Prevention and Treatment of Chemotherapy-induced Oral Mucositis
NCT02816515
A Study on the Effectiveness of Olive Oil Mouthwash in Alleviating Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer.
NCT07293013
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
With two arms to the study:
1. Mouth rinses with chlorhexidine-based solution at a concentration of 0.12%, using as a vehicle to 7% ethyl alcohol.
2. Mouthwashes with solution based only 7% ethyl alcohol.
GOAL. Assess whether there decrease in the rate of oral colonization by gram-negative bacteria in patients with chemotherapy by using chlorhexidine mouthwash.
SPECIFIC OBJECTIVES:
1. The rate of the oral colonization by gram-negative bacteria initiation of chemotherapy.
2. The rate of oral colonization by gram-negative bacteria after 10 days of initiation of chemotherapy.
3. Identify microbiologically gram-negative bacteria colonizing the oral cavity.
SECONDARY OBJECTIVES
1\. The presence of severe neutropenia and fever in each study group during the first 10 days of starting treatment
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chlorhexidine 0.12% & Ethyl Alcohol 7%
Chlorhexidine 0.12% and Ethyl Alcohol 7% mouthwashes 15ml by 30 seconds, twice day for 9 days.
chlorhexidine 0.12%/Ethyl alcohol 7%
Mouth rinses with chlorhexidine 0.12%-based solution
Ethyl Alcohol 7%
Ethyl Alcohol 7% without chlorhexidine mouthwashes 15ml by 30 seconds, twice day for 9 days.
Ethyl Alcohol 7%
Mouth rinses with Ethyl Alcohol 7%-based solution
Chlorhexidine 2% & Ethyl Alcohol 7%
Chlorhexidine 2% and Ethyl Alcohol 7% mouthwashes 15ml by 30 seconds, once day for 3 days.
Chlorhexidine 2%/Ethyl alcohol 7%
Mouth rinses with chlorhexidine 2%-based solution
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
chlorhexidine 0.12%/Ethyl alcohol 7%
Mouth rinses with chlorhexidine 0.12%-based solution
Ethyl Alcohol 7%
Mouth rinses with Ethyl Alcohol 7%-based solution
Chlorhexidine 2%/Ethyl alcohol 7%
Mouth rinses with chlorhexidine 2%-based solution
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Acceptance of participation in the study.
3. Signature of informed consent.
4. Inpatient and remain hospitalized for at least 10 days.
5. The following haematological diagnosis:
1. acute lymphoblastic leukemia.
2. acute myelogenous leukemia.
3. relapsed non-Hodgkin lymphoma.
6. Receiving Chemotherapy scheme as a treatment for the underlying disease
Exclusion Criteria
2. Patients in whom no possible mouthwashes.
3. Patients who willingly choose to withdraw from the study.
4. Patients who develop conditions in which the administration is not possible rinses.
5. Duration of hospital stay less than 10 days, regardless of cause.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidad de Guanajuato
OTHER
Hospital Regional de Alta Especialidad del Bajio
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lauro Fabian Amador Medina
Researcher
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lauro F Amador, Researcher
Role: PRINCIPAL_INVESTIGATOR
Hospital Regional Alta Especialidad Bajio
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Regional Alta Especialidad Bajio
León, Guanajuato, Mexico
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Pitten FA, Kiefer T, Buth C, Doelken G, Kramer A. Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study. J Hosp Infect. 2003 Apr;53(4):283-91. doi: 10.1053/jhin.2002.1391.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Ci-HRAEB-2015-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.